-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
GENEVA, June 17
Xinhua Liu Qu) The World Health Organization (WHO) on the 17th welcomed the recent positive results of the British research team on the treatment of new crown patients, but also warned that the drug should not be used in patients with neo-coronary mild disease or for prevention.
is a synthetic corticosteroid hormone that has been widely used to treat severe allergies, asthma and other diseases at low prices. The first drug to significantly reduce the death rate of new coronary diseases is the first to significantly reduce the death rate of new coronary diseases, according to preliminary results of clinical trials published by a team at the University of Oxford in the United Kingdom.
Director-General Tan Desser congratulated the findings at a regular press conference on the 17th. He confirmed that, based on preliminary findings received by WHO, dexamisson can reduce the death rate by about one-third for new coronary patients using ventilators, and about one-fifth for patients who need oxygen.
is very welcome news for patients who are seriously ill, " says Mr Tandesser. But he also stressed: "The dexamisson has been shown to do little good for patients with mild illness who do not require respiratory support."
Who's Executive Director of the WHO Health Emergency Program, Michael Ryan, also stressed that dexamisson as a "very powerful anti-inflammatory drug" must be used under the supervision of a doctor, "in fact, steroids, especially powerful steroids, may be associated with viral replication." In other words, they can actually promote the division and replication of viruses in the human body. "
", this (dexamison) is not a treatment for the virus itself, nor can it be used to prevent new coronaviruses," Ryan added.
added that while the UK findings were significant, they were still preliminary and that WHO needed to see the final data to update its clinical guidelines and support countries in accessing and using the drug in the most appropriate manner possible.
